Oligonucleotide CDMO Market Expected to Witness a CAGR of 15%

Introduction
- Introduction
- Market Scope
  - Market Definition
  - Segments Covered
  - Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2026-2027)
Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
  - Bottom-Up Approach
  - Top-Down Approach
- Market Forecasting
Executive Summary
- Oligonucleotide CDMO Marke"4">
- Market Overview
  - Market Dynamics
    - Drivers
      - Expanding RNA therapeutics pipeline
      - Rising outsourcing by biotech firms
      - Increasing approvals of oligonucleotide drugs
      - Advancements in synthesis technologies
      - Growing focus on rare genetic disorders
      - Need for scalable and compliant manufacturing
    - Restraints
      - High production costs
      - Complex regulatory requirements
      - Limited manufacturing capacity globally
    - Opportunities
      - Growing demand for personalized and precision medicine
      - Shift toward end-to-end CDMO services
      - Expansion into emerging markets
      - Increasing investment in RNA platforms
    - Key Market Trends
      - Conjugated oligonucleotide development
      - Integration of automation in synthesis
    - Unmet Market Needs
    - Industry Speaks
    - Global Oligonucleotide CDMO Market Size & Forecast (2024-2031), By Service, USD Billion
      - Introduction
      - Contract Manufacturing
        
        Clinical
        
        Commercial
      - Contract Development
    - Global Oligonucleotide CDMO Market Size & Forecast (2024-2031), By Type, USD Billion
      - Introduction
      - Antisense Oligonucleotides
      - Small Interfering RNA
      - Others
    - Global Oligonucleotide CDMO Market Size & Forecast (2024-2031), By Application, USD Billion
      - Introduction
      - Therapeutic
      - Research
      - Diagnostic
      - Others
    - Global Oligonucleotide CDMO Market Size & Forecast (2024-2031), By End User, USD Billion
    - Biotechnology Companies

Company Profiles*

(Business Overview, Financial Performance**, Products & Services Offered, Recent Developments)

Bachem Holding AG

Agilent Technologies

Lonza Group

Thermo Fisher Scientific

WuXi AppTec

ST Pharm Co., Ltd.

Eurofins Scientific

PolyPeptide Group

Ajinomoto Bio-Pharma Services

Aurigene Pharmaceutical Services Ltd

Other Prominent Players

Note: *Indicative list

**For listed companies

Global Oligonucleotide CDMO Market Size, Share, Growth & Trends Report Segmented by Service (Contract Manufacturing & Development), Type (ASOs, siRNA), Application (Therapeutic, Research, Diagnostic), End-user (Biopharma Companies), & Regional Forecast to 2031

Table of Contents

Global Oligonucleotide CDMO Market Size, Share, Growth & Trends Report Segmented by Service (Contract Manufacturing & Development), Type (ASOs, siRNA), Application (Therapeutic, Research, Diagnostic), End-user (Biopharma Companies), & Regional Forecast to 2031

Table of Contents

Related Reports

Global Clinical Trial Central Lab Services Market Size & Trends Report Segmented by Servic...

Global Dental Equipment Market Size & Trends Report Segmented by Product Type (Intraoral &...

Global Bone Void Fillers Market Size & Trends Report Segmented by Type (Demineralized Bone...